Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
Intelligent Bio Solutions (NASDAQ: INBS) has integrated Arabic language support into its Intelligent Fingerprinting Drug Screening System, marking its second international language integration. This strategic move follows the company's early 2025 Middle East expansion plans through partnership with Ivy Diagnostics.
The Arabic integration targets approximately 450 million Arabic speakers across 25 countries, particularly focusing on safety-critical industries, law enforcement, and drug rehabilitation sectors. With the workplace drug testing market in Saudi Arabia projected to reach $64.5 million by 2030, this update enhances accessibility for Arabic-speaking organizations.
This development follows INBS's recent FDA 510(k) submission in December 2024 and planned U.S. market entry in 2025, supporting the company's global expansion strategy across North and South America, Europe, Asia Pacific, and the Middle East, building on its presence in 19 countries.
Intelligent Bio Solutions (NASDAQ: INBS) ha integrato il supporto per la lingua araba nel suo Sistema di Screening per Droga Intelligent Fingerprinting, segnando la sua seconda integrazione linguistica internazionale. Questa mossa strategica segue i piani di espansione dell'azienda nel Medio Oriente nel 2025 attraverso una partnership con Ivy Diagnostics.
L'integrazione araba si rivolge a circa 450 milioni di parlanti arabi in 25 paesi, concentrandosi in particolare su settori critici per la sicurezza, forze dell'ordine e riabilitazione dalle droghe. Con il mercato dei test antidroga sul lavoro in Arabia Saudita previsto a raggiungere 64,5 milioni di dollari entro il 2030, questo aggiornamento migliora l'accessibilità per le organizzazioni di lingua araba.
Questo sviluppo segue la recente presentazione della 510(k) alla FDA da parte di INBS nel dicembre 2024 e l'ingresso previsto nel mercato statunitense nel 2025, supportando la strategia di espansione globale dell'azienda in Nord e Sud America, Europa, Asia Pacifico e Medio Oriente, ampliando la sua presenza in 19 paesi.
Intelligent Bio Solutions (NASDAQ: INBS) ha integrado el soporte para el idioma árabe en su Sistema de Detección de Drogas Intelligent Fingerprinting, marcando su segunda integración lingüística internacional. Este movimiento estratégico sigue los planes de expansión de la compañía en el Medio Oriente para principios de 2025 a través de una asociación con Ivy Diagnostics.
La integración árabe se dirige a aproximadamente 450 millones de hablantes de árabe en 25 países, enfocándose especialmente en industrias críticas para la seguridad, aplicación de la ley y rehabilitación de drogas. Con el mercado de pruebas de drogas en el lugar de trabajo en Arabia Saudita proyectado para alcanzar 64,5 millones de dólares para 2030, esta actualización mejora la accesibilidad para las organizaciones de habla árabe.
Este desarrollo sigue la reciente presentación de la 510(k) a la FDA por parte de INBS en diciembre de 2024 y la entrada planificada al mercado estadounidense en 2025, apoyando la estrategia de expansión global de la compañía en América del Norte y del Sur, Europa, Asia-Pacífico y Medio Oriente, ampliando su presencia en 19 países.
Intelligent Bio Solutions (NASDAQ: INBS)는 Intelligent Fingerprinting 약물 검사 시스템에 아랍어 지원을 통합하여 두 번째 국제 언어 통합을 완료했습니다. 이 전략적 조치는 2025년 중동 확장 계획에 따라 Ivy Diagnostics와의 파트너십을 통해 이루어집니다.
아랍어 통합은 약 4억 5천만 명의 아랍어 사용자를 25개 국가에서 대상으로 하며, 특히 안전이 중요한 산업, 법 집행, 약물 재활 분야에 집중하고 있습니다. 사우디아라비아의 직장 내 약물 검사 시장이 2030년까지 6,450만 달러에 이를 것으로 예상됨에 따라, 이 업데이트는 아랍어를 사용하는 조직의 접근성을 향상시킵니다.
이 발전은 INBS가 2024년 12월에 제출한 FDA 510(k)와 2025년 미국 시장 진출 계획에 이어 이루어지며, 북미 및 남미, 유럽, 아시아 태평양, 중동 전역에서의 글로벌 확장 전략을 지원하고 19개국에서의 입지를 강화합니다.
Intelligent Bio Solutions (NASDAQ: INBS) a intégré le support de la langue arabe dans son Système de Dépistage des Drogues Intelligent Fingerprinting, marquant sa deuxième intégration linguistique internationale. Ce mouvement stratégique fait suite aux plans d'expansion de l'entreprise au Moyen-Orient pour début 2025 grâce à un partenariat avec Ivy Diagnostics.
L'intégration de l'arabe cible environ 450 millions de locuteurs arabes dans 25 pays, en se concentrant particulièrement sur les secteurs critiques pour la sécurité, l'application de la loi et la réhabilitation des drogues. Avec un marché des tests de drogue en milieu de travail en Arabie Saoudite prévu pour atteindre 64,5 millions de dollars d'ici 2030, cette mise à jour améliore l'accessibilité pour les organisations arabophones.
Ce développement fait suite à la récente soumission de la 510(k) à la FDA par INBS en décembre 2024 et à l'entrée prévue sur le marché américain en 2025, soutenant la stratégie d'expansion mondiale de l'entreprise à travers l'Amérique du Nord et du Sud, l'Europe, l'Asie-Pacifique et le Moyen-Orient, tout en renforçant sa présence dans 19 pays.
Intelligent Bio Solutions (NASDAQ: INBS) hat die Unterstützung der arabischen Sprache in sein Intelligent Fingerprinting Drogen-Screening-System integriert, was die zweite internationale Sprachintegration darstellt. Dieser strategische Schritt folgt den Expansionsplänen des Unternehmens im Nahen Osten für Anfang 2025 durch eine Partnerschaft mit Ivy Diagnostics.
Die arabische Integration richtet sich an etwa 450 Millionen arabische Sprecher in 25 Ländern, wobei der Schwerpunkt auf sicherheitskritischen Branchen, Strafverfolgung und Drogenrehabilitation liegt. Da der Markt für Drogentests am Arbeitsplatz in Saudi-Arabien voraussichtlich bis 2030 64,5 Millionen Dollar erreichen wird, verbessert dieses Update die Zugänglichkeit für arabischsprachige Organisationen.
Diese Entwicklung folgt der kürzlichen Einreichung der FDA 510(k) durch INBS im Dezember 2024 und dem geplanten Eintritt in den US-Markt im Jahr 2025, was die globale Expansionsstrategie des Unternehmens in Nord- und Südamerika, Europa, Asien-Pazifik und dem Nahen Osten unterstützt und die Präsenz in 19 Ländern ausbaut.
- Strategic expansion into Middle East market with Arabic language integration
- Access to substantial market opportunity in Saudi Arabia ($64.5M by 2030)
- FDA 510(k) submission completed in December 2024
- Established presence in 19 countries with planned expansion
- None.
Insights
Intelligent Bio Solutions' Arabic language integration for its fingerprinting drug screening system represents strategic market positioning rather than a game-changing business development. While incremental in nature, this localization effort targets the Middle East market methodically following earlier partnership groundwork with Ivy Diagnostics.
The Saudi Arabian workplace drug testing market projection of
This announcement should be viewed as one component of INBS's broader international expansion strategy that includes their FDA 510(k) submission and planned US market entry. For a microcap company operating in 19 countries already, managing multiple geographic expansions simultaneously comes with execution risks, including potential resource dilution across too many markets without achieving meaningful penetration in any single one.
The strategic focus on safety-critical industries, law enforcement, and rehabilitation centers indicates a targeted customer approach, though converting these sectors in Middle Eastern markets will likely require significant relationship building beyond mere product localization.
The integration of Arabic language support into INBS's Intelligent Fingerprinting Drug Screening System enhances accessibility but doesn't fundamentally alter the product's technological capabilities or competitive differentiation. The core value proposition of rapid, non-invasive drug screening remains unchanged.
This localization represents a necessary adaptation for market entry rather than technological advancement. For medical diagnostic devices, local language support significantly impacts usability in clinical settings where technical terminology must be precisely understood by operators. This is particularly relevant in safety-critical environments where testing accuracy directly affects workplace safety protocols.
The fingerprinting approach to drug screening offers workflow advantages in Middle Eastern markets where traditional urine testing may present cultural and practical challenges. The non-invasive nature potentially removes barriers to implementation compared to conventional testing methods.
INBS's multilingual strategy indicates progression toward broader international regulatory and commercial readiness. However, the pending FDA 510(k) submission mentioned represents a more significant near-term catalyst for the company, as US market access would provide substantially larger market opportunity compared to Middle Eastern expansion. This language integration should be viewed as complementary to, rather than a substitute for, achieving major regulatory milestones.
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company’s multilingual upgrade.
The addition of Arabic follows INBS’s previously announced expansion plans in the Middle East in early 2025, through its partnership with Ivy Diagnostics. Arabic is spoken by approximately 450 million people worldwide, holding official status in nearly 25 countries1. With this update, INBS is making its technology more accessible to Arabic-speaking organizations in safety-critical industries, law enforcement and drug rehabilitation, reinforcing its presence in the Middle East and capitalizing on the growing global demand for innovative drug testing solutions.
Integrating the Arabic language into the Company’s portable Drug Screening Reader will improve accessibility and usability for Arabic-speaking organizations in the Middle East. With the workplace drug testing market in Saudi Arabia alone projected to reach
“Expanding language support is a crucial step in ensuring our expanded global reach and accessibility of our solution to organizations worldwide,” said Harry Simeonidis, President & CEO of Intelligent Bio Solutions Inc. “Arabic was a logical choice for the second language integrated into our system, given its wide use across the globe. Adding Arabic to our system strengthens our capabilities and presence in the Middle East and will provide more businesses with an intuitive and reliable drug testing solution.”
The integration of Arabic language marks a key milestone in INBS’ broader international growth strategy, reinforcing its footprint in key markets. The enhancement aligns with the Company’s plans to scale operations across North and South America, Europe, Asia Pacific and the Middle East, expanding on its existing presence in 19 countries. This update builds on INBS’ strategic milestones, including its recent FDA 510(k) submission in December 2024 and planned entry into the multi-billion dollar U.S. market in 2025.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/79dc5c7a-6775-4030-841e-7922be3fea9a
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.
1 United Nations 2024. World Arabic Language Day, 18 December. Available at: https://www.un.org/en/observances/arabiclanguageday/
2 Grand View Research, 2024. Saudi Arabia Employer And Workplace Drug Testing Market Size & Outlook Available at: https://www.grandviewresearch.com/horizon/outlook/employer-and-workplace-drug-testing-market/saudi-arabia/
FAQ
What is the market potential for INBS in Saudi Arabia's workplace drug testing sector?
How many countries does INBS currently operate in?
When did INBS submit its FDA 510(k) application?
What is the reach of INBS's Arabic language integration for its drug screening system?
When is INBS planning to enter the U.S. market?
